GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
75.62
-0.69 (-0.90%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close76.31
Open76.00
Bid0.00 x 900
Ask0.00 x 1200
Day's Range75.14 - 76.29
52 Week Range64.27 - 89.54
Volume4,075,281
Avg. Volume6,370,215
Market Cap98.029B
Beta (3Y Monthly)1.40
PE Ratio (TTM)45.17
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.28 (3.10%)
Ex-Dividend Date2018-09-13
1y Target EstN/A
Trade prices are not sourced from all markets
  • Can This Tiny Biotech Revolutionize a $35 Billion Market?
    Motley Foolyesterday

    Can This Tiny Biotech Revolutionize a $35 Billion Market?

    This upstart is developing a diagnostic test and treatment for nonalcoholic steatohepatitis, or NASH, an increasingly common liver disease.

  • Forget Gilead Sciences: Intercept Pharmaceuticals, Inc. Is a Better Growth Stock
    Motley Fool2 days ago

    Forget Gilead Sciences: Intercept Pharmaceuticals, Inc. Is a Better Growth Stock

    Gilead's high-flying days are seemingly over. Intercept Pharmaceuticals, on the other hand, is only getting started.

  • Gauging Analysts’ Views of Sarepta Stock in October
    Market Realist2 days ago

    Gauging Analysts’ Views of Sarepta Stock in October

    Of the 23 analysts covering Sarepta Therapeutics (SRPT) in October, eight analysts gave the stock a “strong buy” rating, 14 analysts gave it a “buy” rating, and one analyst gave Sarepta Therapeutics a “hold” rating.

  • Trump administration: Drug makers should disclose prices in TV ads
    Yahoo Finance2 days ago

    Trump administration: Drug makers should disclose prices in TV ads

    just after drug companies announced they will be disclosing prices of drugs advertised on TV via a website, the Trump administration proposes a rule to require medicare and medicaid drugs to disclose price in TV ads.

  • A Look at Sarepta Therapeutics’ Stock Performance
    Market Realist3 days ago

    A Look at Sarepta Therapeutics’ Stock Performance

    Sarepta Therapeutics (SRPT) has a sponsored research and exclusive license option agreement with Genethon for advancing the latter’s microdystrophin gene therapy program. Sarepta also has a sponsored research and exclusive license option agreement with Duke University for advancing its gene-editing CRISPR/Cas9 technology for muscular dystrophy. Sarepta had submitted a marketing authorization application (or MAA) for eteplirsen to the European Medicines Agency (or EMA) in November 2016.

  • Key Collaborations Bode Well for Sarepta Therapeutics
    Market Realist3 days ago

    Key Collaborations Bode Well for Sarepta Therapeutics

    Sarepta Therapeutics (SRPT) is working with several strategic partners for developing multiple treatment approaches to DMD. These partners include Nationwide Children’s Hospital, Myonexus, Genethon, Duke University, and Summit Limited.

  • 2 Pharmaceutical Stocks to Buy With Dividends of 3% or Better
    Motley Fool3 days ago

    2 Pharmaceutical Stocks to Buy With Dividends of 3% or Better

    A bad week for the broad market made some generous payouts even more attractive.

  • Analyzing Sarepta’s Product Pipeline
    Market Realist3 days ago

    Analyzing Sarepta’s Product Pipeline

    Sarepta Therapeutics’ (SRPT) Exondys 51 uses exon-skipping technology to skip exon 51 of the DMD gene. The drug is designed to bind to exon 51, which leads to an exclusion or skipping of this exon during mRNA processing. Golodirsen uses exon-skipping technology to skip exon 53 of the DMD gene. 

  • Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
    Zacks5 days ago

    Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

    In the latest trading session, Gilead Sciences (GILD) closed at $73.59, marking a +1.5% move from the previous day.

  • Understanding Sarepta Therapeutics’ Operational Performance
    Market Realist5 days ago

    Understanding Sarepta Therapeutics’ Operational Performance

    Sarepta Therapeutics’ (SRPT) cost of sales increased from $506,000 in the second quarter of 2017 to $6.73 million in the second quarter. Sarepta’s cost of sales primarily consists of inventory costs, overhead costs, and royalty payments to BioMarin Pharmaceutical (BMRN). These royalty payments resulted from the settlement and licenses agreements in July 2017. Sarepta Therapeutics’ gross income increased from $34.48 million in the second quarter of 2017 to $66.8 million in the second quarter.

  • Why a Peninsula cancer fighter soared nearly 40% after record-breaking IPO
    American City Business Journals6 days ago

    Why a Peninsula cancer fighter soared nearly 40% after record-breaking IPO

    As the market fell sharply Thursday, this biotech boomed after raising $324 million in an initial public offering.

  • Healthcare Stocks in the Red amid Broader Market Sell-Off
    Market Realist7 days ago

    Healthcare Stocks in the Red amid Broader Market Sell-Off

    Yesterday, most healthcare stocks were trading below their previous day’s closing price. Biotech players seem to have been hit the worst. However, all other sectors including pharmaceuticals, medical devices, and hospitals saw significant weakness. Johnson & Johnson (JNJ), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb fell 1.1%, 2.1%, 2.6%, and 3.9%, respectively, yesterday. Major biotechnology players Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), and Novo Nordisk (NVO) fell 2.30%, 2.33%, 2.04%, and 1.81%, respectively.

  • Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates
    Zacks8 days ago

    Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates

    Arbutus Biopharma (ABUS) provides updates on its HBV development programs. However, uncertainty and early to mid-stage of development remains a concern.

  • Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status
    Zacks8 days ago

    Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status

    Data presentations by leading sector players take center stage this week.

  • Celgene: Analysts’ Views before Its Third-Quarter Earnings
    Market Realist8 days ago

    Celgene: Analysts’ Views before Its Third-Quarter Earnings

    Wall Street analysts expect Celgene to report a net income and EPS of $1.2 billion and $1.71, respectively, in the third quarter.

  • Better Buy: Crispr Therapeutics AG vs. Editas
    Motley Fool8 days ago

    Better Buy: Crispr Therapeutics AG vs. Editas

    Which gene editing start-up has the best chance to outperform in the years ahead?

  • Simply Wall St.9 days ago

    Estimating The Intrinsic Value Of Gilead Sciences Inc (NASDAQ:GILD)

    How far off is Gilead Sciences Inc (NASDAQ:GILD) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is Read More...

  • Gilead Sciences Stock: Analysts’ Recommendations
    Market Realist10 days ago

    Gilead Sciences Stock: Analysts’ Recommendations

    In October, of the 28 analysts covering Gilead Sciences (GILD), 18 analysts gave the stock a “buy” or higher rating, while ten analysts gave the stock a “hold” rating. The mean rating for Gilead Sciences stock is 2.14 with a target price of $87.96, which implies an upside potential of 14.9% over the company’s closing price of $76.56 on October 4.

  • Taking Stock of Gilead’s Operational Performance
    Market Realist10 days ago

    Taking Stock of Gilead’s Operational Performance

    Gilead Sciences’ (GILD) selling, general, and administrative expenses increased from $897.0 million in the second quarter of 2017 to $980.0 million in the second quarter. The increase was due to higher stock-based compensation expenses and costs after the Kite acquisition.

  • Gilead Sciences (GILD) Stock Moves -0.24%: What You Should Know
    Zacks12 days ago

    Gilead Sciences (GILD) Stock Moves -0.24%: What You Should Know

    In the latest trading session, Gilead Sciences (GILD) closed at $76.24, marking a -0.24% move from the previous day.

  • Cara Therapeutics: Performance and Estimates for Q3
    Market Realist12 days ago

    Cara Therapeutics: Performance and Estimates for Q3

    Cara Therapeutics (CARA) is a clinical-stage biotechnology company that develops new chemical entities for managing pain and pruritus. It reported EPS of -$0.52 on revenues of $2.87 million in the second quarter.

  • Gilead Sciences: What to Expect from the Top Line
    Market Realist13 days ago

    Gilead Sciences: What to Expect from the Top Line

    Gilead Sciences (GILD) generated total revenues of $5.65 billion in the second quarter—compared to $7.14 billion in the second quarter of 2017. The company generates revenues from sales of products and royalties and contract arrangements. Gilead Sciences’ product sales decreased from $7.05 billion in the second quarter of 2017 to $5.54 billion in the second quarter. The company’s royalty, contract, and other revenues increased from $95.0 million in the second quarter of 2017 to $108.0 million in the second quarter.

  • Analyzing Gilead Sciences’ Research Pipeline Developments
    Market Realist13 days ago

    Analyzing Gilead Sciences’ Research Pipeline Developments

    On October 3, Gilead Sciences (GILD) reported the results from a phase three study evaluating the safety and efficacy of Biktarvy for treating HIV-1 infections in treatment-naive patients. The drug was found to be statistically non-inferior to a regimen of abacavir, dolutegravir, and lamivudine through 96 weeks of therapy.

  • How’s Gilead Sciences Positioned in October?
    Market Realist13 days ago

    How’s Gilead Sciences Positioned in October?

    For Gilead Sciences (GILD), falling revenues and recent gains in the stock price have kept investors interested in the stock. A slew of key collaboration and licensing arrangements have piqued investors’ interest in the company’s research programs.

  • Gilead Announces Positive Data From Ongoing Biktarvy Study
    Zacks13 days ago

    Gilead Announces Positive Data From Ongoing Biktarvy Study

    Gilead (GILD) reports positive data from an ongoing late stage study on HIV regimen, Biktarvy at 96 weeks.